Kura Oncology (NASDAQ:KURA) Earns Outperform Rating from Wedbush

Kura Oncology (NASDAQ:KURA)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research report issued to clients and investors on Thursday,RTT News reports. They currently have a $36.00 target price on the stock. Wedbush’s target price would suggest a potential upside of 364.52% from the stock’s previous close.

KURA has been the topic of a number of other reports. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. Jefferies Financial Group cut their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Finally, Bank of America dropped their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Price Performance

KURA stock traded down $0.02 during mid-day trading on Thursday, reaching $7.75. The company’s stock had a trading volume of 357,742 shares, compared to its average volume of 1,584,997. The stock has a market cap of $602.67 million, a PE ratio of -3.28 and a beta of 0.78. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company’s 50 day moving average is $8.19 and its two-hundred day moving average is $13.92.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. Equities research analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Insiders Place Their Bets

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently modified their holdings of KURA. China Universal Asset Management Co. Ltd. grew its position in shares of Kura Oncology by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after buying an additional 5,788 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in Kura Oncology by 21.9% during the third quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock valued at $924,000 after purchasing an additional 8,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock worth $579,000 after purchasing an additional 7,722 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Kura Oncology during the 3rd quarter worth $298,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Kura Oncology by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after buying an additional 14,106 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.